Skip to main content

Moderna’s stock boosted by positive data from trial of melanoma treatment combined with Merck’s Keytruda

Moderna's stock was on track for its biggest one-day gain in more than a year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.